Basic Information
| LncRNA/CircRNA Name | ASBEL |
| Synonyms | NA |
| Region | GRCh38_21:17611744-17633199 |
| Ensemble | ENSG00000280594 |
| Refseq | NR_149073 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | osteosarcoma |
| ICD-0-3 | NA |
| Methods | qRT-PCR, Western blot, in vitro knockdown |
| Sample | osteoblast cell line hFOB1.19 and human osteosarcoma cell line MG63, osteosarcoma cell line OS-732 |
| Expression Pattern | up-regulated |
| Function Description | ASBEL was highly expressed in osteosarcoma cells. Knockdown of ASBEL inhibited osteosarcoma cell viability, migration, and invasion, as well as the expression level of miR-21. PP2A was a direct target of miR-21, which participated in the effects of ASBEL and miR-21 on the activation of phosphatidylinositol 3-kinase/protein kinase 3/glycogen synthase kinase-3B (PI3K/AKT/GSK3B) and mitogen-activated protein kinase/extracellular regulated protein kinase (MEK/ERK) signaling pathways as well as the enhancement of osteosarcoma cell proliferation, migration, and invasion. |
| Pubmed ID | 29323740 |
| Year | 2018 |
| Title | Long non-coding RNA ASBEL promotes osteosarcoma cell proliferation, migration, and invasion by regulating microRNA-21. |
External Links
| Links for ASBEL | GenBank HGNC NONCODE |
| Links for osteosarcoma | OMIM COSMIC |